From an epidemiological standpoint, voriconazole plays a crucial role in managing fungal diseases that have significant morbidity and mortality rates. Fungal infections can be particularly devastating in immunocompromised populations, such as those with HIV/AIDS, cancer patients undergoing chemotherapy, or organ transplant recipients. Tracking the usage and effectiveness of voriconazole helps epidemiologists understand the spread, control, and resistance patterns of these infections.
